1-20 of 46
Elza Lomaia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Atherosclerosis Risk Factors in Chronic Myeloid Leukemia Patients Under Durable Tyrosine Kinase Inhibitors Therapy

Nadezhda Shnalieva, Iurii Osipov, Darina Zammoeva, Pavel Kabanov, Oxana Rotar, Maria Boyarinova, Marina Dyshluk, Galina Salogub, Elena Vasilieva, Elza Lomaia
Journal: Blood
Blood (2024) 144 (Supplement 1): 6617.
https://doi.org/10.1182/blood-2024-211387
Published: 2024
Journal Articles

Long-Term Outcomes in Blastic Phase Chronic Myeloid Leukemia - One Center Experience

Darina Zammoeva, Yulia Alexeeva, Dmitry Motorin, Ekaterina Ovsyannikova, Olga Kulemina, Renat Badaev, Nadezhda Shnalieva, Vladimir Ivanov, Galina Salogub, Aleksina Shatilova, Larisa Girshova, Nadiya Siordiya, Irina Budaeva, Elza Lomaia
Journal: Blood
Blood (2024) 144 (Supplement 1): 6616.
https://doi.org/10.1182/blood-2024-211328
Published: 2024
Journal Articles

Long-Term Outcomes after Allogeneic Stem Cell Transplantation Versus New Generation Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia

Elza Lomaia, Olga Kulemina, Julia Vlasova, Julia Matvienko, Julia Yakovleva, Ekaterina Ovsyannikova, Renat Badaev, Evgeniya Sbityakova, Yulia Alexeeva, Elena Morozova
Journal: Blood
Blood (2024) 144 (Supplement 1): 6607.
https://doi.org/10.1182/blood-2024-209932
Published: 2024
Journal Articles

Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses

Elias Jabbour, Omer Jamy, Paul B. Koller, Vivian G. Oehler, Maria R. Baer, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Jorge E. Cortes, Sudipto Mukherjee, Dennis Dong Hwan Kim, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Huanshan Guo, Zi Chen, Hengbang Wang, Tommy Fu, Lixin Jiang, Zhihong Yang, Cunlin Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 3151.
https://doi.org/10.1182/blood-2024-207139
Published: 2024
Journal Articles

Myeloid Sarcoma or Extramedullary Acute Myeloid Leukemia: Experience in Managing Single-Centre Patients Cohort

Aleksina Shatilova, Irina Budaeva, Yuliya Matvienko, Yuliya Mirolyubova, Darya Ryzhkova, Roman Grozov, Konstantin Bogdanov, Elza Lomaia, Olga Kulemina, Renat Badaev, Nadezhda Shnalieva, Yulia Alexeeva, Vladimir Ivanov, Larisa Girshova
Journal: Blood
Blood (2024) 144 (Supplement 1): 5987.
https://doi.org/10.1182/blood-2024-211246
Published: 2024
Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Jorge E. Cortes, Michael W. Deininger, Jane Apperley, Chrisopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James McCloskey, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Maria Undurraga, Lin Yang, Alexander Vorog, Tammie Yeh, L. Evan Reddick, Niti Patel, Hagop M. Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 3148.
https://doi.org/10.1182/blood-2024-207634
Published: 2024
Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Michael Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergei Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Jorge Cortes, Andre N.R. Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García Gutiérrez, Koji Sasaki, Carla Maria Boquimpani De Moura Freitas, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4536.
https://doi.org/10.1182/blood-2023-186854
Published: 2023
Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F Apperley
Journal: Blood
Blood (2023) 142 (Supplement 1): 3164.
https://doi.org/10.1182/blood-2023-178790
Published: 2023
Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 866.
https://doi.org/10.1182/blood-2023-182100
Published: 2023
Journal Articles

The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia

Elena Kuzmina, Ekaterina Chelysheva, Elza Lomaia, Elena V Morozova, Oleg Shukhov, Anna Petrova, Tamara Chitanava, Julia Vlasova, Evgenia Sbitiakova, Natalia Lazorko, Irina Nemchenko, Anastasiya Vitalievna Bykova, Margarita Gurianova, Alina Kokhno, Anna Turkina
Journal: Blood
Blood (2023) 142 (Supplement 1): 1803.
https://doi.org/10.1182/blood-2023-181789
Published: 2023
Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Elias Jabbour, Hagop M. Kantarjian, Paul B. Koller, Omer Jamy, Vivian G. Oehler, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Jorge Cortes, Huanshan Guo, Zi Chen, Lei Fu, Hengbang Wang, Lixin Jiang, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1798.
https://doi.org/10.1182/blood-2023-187744
Published: 2023
Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio
Journal: Blood
Blood (2022) 140 (Supplement 1): 195–197.
https://doi.org/10.1182/blood-2022-167177
Published: 2022
Journal Articles

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamová, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Strömberg, Jiri Mayer, Franck E. Nicolini, Han Bao, Fausto Castagnetti, Elzbieta Patkowska, Klaus Hirschbühl, Edyta Paczkowska, Anne Parry, Astghik Voskanyan, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Krzysztof Lewandowski, Stefan W. Krause, Elke Dammann, Peter Anhut, Justyna Gil, Thomas Südhoff, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Journal: Blood
Blood (2022) 140 (Supplement 1): 818–820.
https://doi.org/10.1182/blood-2022-162252
Published: 2022
Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge E. Cortes, Michael W. Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F. Apperley
Journal: Blood
Blood (2022) 140 (Supplement 1): 1495–1497.
https://doi.org/10.1182/blood-2022-157822
Published: 2022
Journal Articles

Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia

Anna Turkina, Elena A. Kuzmina, Elza Lomaia, Elena Morozova, Oleg A. Shukhov, Anna N. Petrova, Tamara Chitanava, Julia J. Vlasova, Ekaterina Yu. Chelysheva, Evgeniya Sbityakova, Irina S. Nemchenko, Anastasiya V. Bykova, Margarita A. Gurianova, Alina V. Kokhno, Elena N. Parovichnikova
Journal: Blood
Blood (2022) 140 (Supplement 1): 9654–9655.
https://doi.org/10.1182/blood-2022-162268
Published: 2022
Journal Articles

Comparative Characteristics of the Effectiveness of Tyrosine Kinase Inhibitors Vs Allogeneic Hematopoietic Stem Cell Transplantation in the Chronic Phase of Chronic Myeloid Leukemia

Elza Lomaia, Tamara Chitanava, Yulia Vlasova, Dmitry Motorin, Sergey Voloshin, Darina Zammoeva, Renat Badaev, Yulia Matvienko, Elizaveta Efremova, Ekaterina Mileeva, Nadia Siordia, Olga Kulemina, Eugenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Irina Martynkevich, Elena Karyagina, Natalia Ilyina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Svetlana Stepanova, Vasily Shuvaev, Elena Morozova
Journal: Blood
Blood (2022) 140 (Supplement 1): 12192–12193.
https://doi.org/10.1182/blood-2022-163506
Published: 2022
Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Jane F. Apperley, Jorge E. Cortes, Elias Jabbour, Andreas Hochhaus, Timothy Hughes, Charles Chuah, Hugues de Lavallade, Michael W. Deininger, Jeffrey H. Lipton, Elza Lomaia, Lori Maness, Michael Mauro, James McCloskey, Beatriz Moiraghi, Carolina Pavlovsky, Christine Rojas, Philippe Rousselot, Tomasz Sacha, Moshe Talpaz, Anna Turkina, Maria Undurraga Sutton, Xiaowei Ren, Alexander Vorog, Gianantonio Rosti
Journal: Blood
Blood (2022) 140 (Supplement 1): 6760–6762.
https://doi.org/10.1182/blood-2022-157956
Published: 2022
Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Clinical Trials & Observations
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Journal: Blood
Blood (2021) 138 (21): 2031–2041.
https://doi.org/10.1182/blood.2020009984
Published: 2021
Includes: Supplemental data
Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Clinical Trials & Observations
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Kevin Arthur, Lori Maness, Moshe Talpaz, Michael Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger
Journal: Blood
Blood (2021) 138 (21): 2042–2050.
https://doi.org/10.1182/blood.2021012082
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani
Journal: Blood
Blood (2021) 138 (Supplement 1): 310.
https://doi.org/10.1182/blood-2021-152561
Published: 2021